CAS 1446090-77-2

Formula: C25H17F3N4O3

InChI: InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1

InChI key: NGFFVZQXSRKHBM-FKBYEOEOSA-N

SMILES: C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F

rel-5-(((1R,1aS,6bR)-1-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one

CAS: 1446090-77-2

rel-5-(((1R,1aS,6bR)-1-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one

Formula: C₂₅H₁₇F₃N₄O₃

Purity: 95%

Molecular weight: 478.42

Ref: 54-PC1039919

Benzofuran Impurity 3

CAS: 1446090-77-2

Formula: C₂₅H₁₇F₃N₄O₃

Molecular weight: 478.43

Ref: 4Z-B-104027

Lifirafenib

CAS: 1446090-77-2

Lifirafenib is a targeted anticancer therapy, which is a small molecule inhibitor sourced through pharmaceutical development processes. Its mode of action involves the selective inhibition of the RAF kinase family, including B-RAF, which plays a critical role in the MAPK/ERK signaling pathway. By targeting these kinases, Lifirafenib effectively disrupts the aberrant signaling that contributes to tumor growth and survival in certain cancers with mutations such as BRAF V600E.

Formula: C₂₅H₁₇F₃N₄O₃

Purity: Min. 95%

Molecular weight: 478.42 g/mol

Ref: 3D-WHC09077